Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group

Blood (2010) 116 (17): 3171–3179.

https://doi.org/10.1182/blood-2010-03-276196

Published: 2010

Journal Articles

Rituximab (R) Maintenance Versus Observation After Short Term Chemoimmunotherapy R-FND as First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Updated Results and Safety of the Maintenance of An Intergruppo Italiano Linfomi (IIL) Randomized Trial.

Blood (2009) 114 (22): 1706.

https://doi.org/10.1182/blood.V114.22.1706.1706

Published: 2009

Journal Articles

Distinct roles of helper T-cell subsets in a systemic autoimmune disease

Katrina K. Hoyer, Wilson F. Kuswanto, Eugenio Gallo, Abul K. Abbas

Blood (2009) 113 (2): 389–395.

https://doi.org/10.1182/blood-2008-04-153346

Published: 2009

Includes: Supplemental data

Journal Articles

Brief Chemoimmunotherapy Rituximab (R)-FND ± R Maintenance as First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Preliminary Analysis of a Prospective Randomized IIL Trial

Blood (2008) 112 (11): 834.

https://doi.org/10.1182/blood.V112.11.834.834

Published: 2008

Journal Articles

Mid-Treatment Evaluation of 18-FDG-Positron Emission Tomography/Computed Tomography (PET) as Predictive Value of Response Assessment in Aggressive Non Hodgkin Lymphoma (NHL).

Patrizia Pregno, Annalisa Chiappella, Daniele Penna, Marilena Bellò, Giulia Benevolo, Barbara Botto, Roberto Freilone, Lorella Orsucci, Sabrina Scaglia, Giovanni Bisi, Umberto Vitolo, Eugenio Gallo

Blood (2007) 110 (11): 2333.

https://doi.org/10.1182/blood.V110.11.2333.2333

Published: 2007

Journal Articles

Rituximab (R) in Addition to Dose-Dense Chemotherapy MegaCEOP and Intensification with R-MAD Followed by High Dose Chemotherapy BEAM with Autologous Stem Cell Transplantation (ASCT) Is Safe and Effective in Untreated High Risk Diffuse Large B-Cell Lymphoma (DLBCL).

Annalisa Chiappella, Giuseppe Rossi, Maria Giuseppina Cabras, Anna Marina Liberati, Giovannino Ciccone, Flavia Salvi, Emanuele Angelucci, Barbara Botto, Antonella Darbesio, Roberto Freilone, Lorella Orsucci, Vincenzo Pavone, Enrico Maria Pogliani, Umberto Ricardi, Delia Rota-Scalabrini, Anna Tonso, Alessandra Tucci, Eugenio Gallo, Umberto Vitolo

Blood (2007) 110 (11): 1899.

https://doi.org/10.1182/blood.V110.11.1899.1899

Published: 2007

Journal Articles

Radioimmunotherapy (RIT) with 90 Y-Ibritumomab Tiuxetan (Zevalin) for the Treatment of Relapsed or Resistant Aggressive Diffuse Large B-Cell Lymphoma (DLBCL) Heavily Pretreated with Rituximab + Chemotherapy: A GIMURELL Experience.

Barbara Botto, Marilena Bellò, Giulia Benevolo, Maria Giuseppina Cabras, Claudia Castellino, Annalisa Chiappella, Giuseppe Fioritoni, Roberto Freilone, Maurizio Martelli, Lorella Orsucci, Patrizia Pregno, Paola Scapoli, Anna Tonso, Giovanni Bisi, Umberto Vitolo, Eugenio Gallo

Blood (2007) 110 (11): 4478.

https://doi.org/10.1182/blood.V110.11.4478.4478

Published: 2007

Journal Articles

Protein Expression of p15 and p21 Plays an Unfavorable Prognostic Role in Adult Acute Lymphoblastic Leukemia (ALL) Patients Independently of Their Gene Promoter Methylation Status.

Blood (2007) 110 (11): 2802.

https://doi.org/10.1182/blood.V110.11.2802.2802

Published: 2007

Journal Articles

Front-Line Brief Chemo-Immunotherapy Rituximab (R)-FND + Rituximab Consolidation ± Rituximab Maintenance in Elderly Patients with Untreated Advanced Stage Follicular Lymphoma (FL): First Interim Analysis of a Prospective Randomized Study (ML17638)

Blood (2007) 110 (11): 1278.

https://doi.org/10.1182/blood.V110.11.1278.1278

Published: 2007

Journal Articles

Palifermin in Patients with Hematological Malignancies Undergoing Autologous Hematopoietic Stem Cell Transplantation (HSCT): The Italian Early Access Program (EAP).

Laura M. Cavagna, MD, Gaetano Bonifacio, MD, Emanuele Angelucci, MD, Alessandro Fanni, MD, Giuseppe Milone, MD, Eugenio Gallo, MD, Elena Benincasa, MD

Blood (2006) 108 (11): 5236.

https://doi.org/10.1182/blood.V108.11.5236.5236

Published: 2006

Journal Articles

Prognostic Role of Transfusion Requirement and Validation of the IPSS Prognostic System in Myelodisplastic Syndromes.

Blood (2006) 108 (11): 2622.

https://doi.org/10.1182/blood.V108.11.2622.2622

Published: 2006

Journal Articles

Protein Expression and Methylation Status of the CKI p21, p15 and p16 in Adult Acute Lymphoblastic Leukemia (ALL) Patients: Prognostic Implications.

Chiara Gregorj, PhD, Fabiana De Cave, MS, Maria Teresa Petrucci, MD, Maria R. Ricciardi, PhD, Maria C. Scerpa, MS, Sara Santinelli, Vincenzo Liso, MD, Rosario Giustolisi, MD, Andrea Camera, MD, Eugenio Gallo, MD, Felicetto Ferrara, MD, Francesco Nobile, MD, Nicola Cascavilla, MD, Francesco Fabbiano, MD, Giuseppe Leone, MD, Omar Perbellini, MD, Patrizio Mazza, MD, Luciana Annino, MD, Piero Galieni, MD, Eustachio Miraglia, MD, Massimo Martelli, MD, Giuseppe Torelli, MD, Nicola Cantore, MD, Antonio Peta, MD, Alfonso M. D’Arco, MD, Alessandra Tedeschi, MD, Giuseppe Fioritoni, MD, Antonio Cuneo, MD, Maura Brugiatelli, MD, Gianluca Gaidano, MD, PhD, Giuseppe Visani, MD, Ignazio Majolino, MD, Rosa Nieddu, MD, Mario Boccadoro, MD, Ernesto Capussela, MD, Antonella Vitale, MD, Giovanna Meloni, MD, Paola Fazzi, MD, PhD, Marco Vignetti, MD, Robert Foa, MD, Agostino Tafuri, MD

Blood (2006) 108 (11): 1843.

https://doi.org/10.1182/blood.V108.11.1843.1843

Published: 2006

Journal Articles

Rituximab as Adjuvant to Dose-Dense and High Dose Chemotherapy (HDC) with Autologous Stem Cell Transplantation (ASCT) as First Line Treatment in Stage III–IV Diffuse Large B-Cell Lymphoma (DLBCL) at Poor Prognosis: Final Analysis of Phase II GIMURELL Trial.

Blood (2006) 108 (11): 329.

https://doi.org/10.1182/blood.V108.11.329.329

Published: 2006

Journal Articles

Prognostic Evaluation of Myelodysplastic Syndromes (MDS): Analysis of Deaths Due to Age-Related Causes.

Blood (2005) 106 (11): 2543.

https://doi.org/10.1182/blood.V106.11.2543.2543

Published: 2005

Journal Articles

Pre-Autologous Stem Cell Transplantation (ASCT) Treatment with Rituximab Does Not Impair Stem Cell Harvest and Engraftment in Untreated Patients with Diffuse Large B-Cell Lymphoma (B-DLCL) at Poor Prognosis.

Blood (2005) 106 (11): 2738.

https://doi.org/10.1182/blood.V106.11.2738.2738

Published: 2005

Journal Articles

Effect of Adding Rituximab (R) to Induction Treatment and High Dose Chemotherapy (HDC) Prior to Autologous Stem Cell Transplantation (ASCT) as First Line Therapy in Stage III-IV Diffuse Large B-Cell Lymphoma (B-DLCL) at Poor Prognosis.

Blood (2005) 106 (11): 676.

https://doi.org/10.1182/blood.V106.11.676.676

Published: 2005

Journal Articles

Sequential Brief Chemo-Immunotherapy FND + Rituximab in Elderly Patients with Advanced Stage Follicular Lymphoma (FL): High Clinical and Molecular Remission Rate Associated with a Prolonged Failure-Free Survival.

Blood (2004) 104 (11): 1320.

https://doi.org/10.1182/blood.V104.11.1320.1320

Published: 2004

Journal Articles

Concurrent Rituximab with Dose-Dense MegaCEOP Chemotherapy and High Dose Mitoxantrone, Ara-C and Dexamethasone (MAD) Followed by BEAM and Autologous Stem Cell Transplantation (ASCT) Is Feasible and Effective in High Risk Diffuse Large B-Cell Lymphoma (B-DLCL): A Multicenter Pilot Study.

Umberto Vitolo, Anna Marina Liberati, Maria Giuseppina Cabras, Giuseppe Rossi, Alessandro Levis, Enzo Pavone, Emanuele Angelucci, Carola Boccomini, Lisa Bonello, Barbara Botto, Annalisa Chiappella, Francesco Di Vito, Isabella Palumbo, Enrico Pogliani, Delia Rota-Scalabrini, Flavia Salvi, Anna Tonso, Alessandra Tucci, Eugenio Gallo

Blood (2004) 104 (11): 1321.

https://doi.org/10.1182/blood.V104.11.1321.1321

Published: 2004

Journal Articles

Incidence of Invasive Aspergillosis in Allogeneic Stem Cell Transplantation Patients: An Italian Prospectic Multicenter Study.

Nicola Mordini, MD, Benedetto Bruno, MD, Alessandro Busca, MD, Roberto Sorasio, MD, Mario Boccadoro, PHD, Eugenio Gallo, PHD, Andrea Gallamini, MD, Daniele Mattei, MD

Blood (2004) 104 (11): 5057.

https://doi.org/10.1182/blood.V104.11.5057.5057

Published: 2004

Journal Articles

Front-Line Treatment of Acute Promyelocytic Leukemia with AIDA Induction Followed by Risk-Adapted Consolidation: Results of the AIDA-2000 Trial of the Italian GIMEMA Group.

Blood (2004) 104 (11): 392.

https://doi.org/10.1182/blood.V104.11.392.392

Published: 2004

NARROW

Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group

Rituximab (R) Maintenance Versus Observation After Short Term Chemoimmunotherapy R-FND as First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Updated Results and Safety of the Maintenance of An Intergruppo Italiano Linfomi (IIL) Randomized Trial.

Distinct roles of helper T-cell subsets in a systemic autoimmune disease

Brief Chemoimmunotherapy Rituximab (R)-FND ± R Maintenance as First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Preliminary Analysis of a Prospective Randomized IIL Trial

Mid-Treatment Evaluation of 18-FDG-Positron Emission Tomography/Computed Tomography (PET) as Predictive Value of Response Assessment in Aggressive Non Hodgkin Lymphoma (NHL).

Rituximab (R) in Addition to Dose-Dense Chemotherapy MegaCEOP and Intensification with R-MAD Followed by High Dose Chemotherapy BEAM with Autologous Stem Cell Transplantation (ASCT) Is Safe and Effective in Untreated High Risk Diffuse Large B-Cell Lymphoma (DLBCL).

Radioimmunotherapy (RIT) with 90 Y-Ibritumomab Tiuxetan (Zevalin) for the Treatment of Relapsed or Resistant Aggressive Diffuse Large B-Cell Lymphoma (DLBCL) Heavily Pretreated with Rituximab + Chemotherapy: A GIMURELL Experience.

Protein Expression of p15 and p21 Plays an Unfavorable Prognostic Role in Adult Acute Lymphoblastic Leukemia (ALL) Patients Independently of Their Gene Promoter Methylation Status.

Front-Line Brief Chemo-Immunotherapy Rituximab (R)-FND + Rituximab Consolidation ± Rituximab Maintenance in Elderly Patients with Untreated Advanced Stage Follicular Lymphoma (FL): First Interim Analysis of a Prospective Randomized Study (ML17638)

Palifermin in Patients with Hematological Malignancies Undergoing Autologous Hematopoietic Stem Cell Transplantation (HSCT): The Italian Early Access Program (EAP).

Prognostic Role of Transfusion Requirement and Validation of the IPSS Prognostic System in Myelodisplastic Syndromes.

Protein Expression and Methylation Status of the CKI p21, p15 and p16 in Adult Acute Lymphoblastic Leukemia (ALL) Patients: Prognostic Implications.

Rituximab as Adjuvant to Dose-Dense and High Dose Chemotherapy (HDC) with Autologous Stem Cell Transplantation (ASCT) as First Line Treatment in Stage III–IV Diffuse Large B-Cell Lymphoma (DLBCL) at Poor Prognosis: Final Analysis of Phase II GIMURELL Trial.

Prognostic Evaluation of Myelodysplastic Syndromes (MDS): Analysis of Deaths Due to Age-Related Causes.

Pre-Autologous Stem Cell Transplantation (ASCT) Treatment with Rituximab Does Not Impair Stem Cell Harvest and Engraftment in Untreated Patients with Diffuse Large B-Cell Lymphoma (B-DLCL) at Poor Prognosis.

Effect of Adding Rituximab (R) to Induction Treatment and High Dose Chemotherapy (HDC) Prior to Autologous Stem Cell Transplantation (ASCT) as First Line Therapy in Stage III-IV Diffuse Large B-Cell Lymphoma (B-DLCL) at Poor Prognosis.

Sequential Brief Chemo-Immunotherapy FND + Rituximab in Elderly Patients with Advanced Stage Follicular Lymphoma (FL): High Clinical and Molecular Remission Rate Associated with a Prolonged Failure-Free Survival.

Concurrent Rituximab with Dose-Dense MegaCEOP Chemotherapy and High Dose Mitoxantrone, Ara-C and Dexamethasone (MAD) Followed by BEAM and Autologous Stem Cell Transplantation (ASCT) Is Feasible and Effective in High Risk Diffuse Large B-Cell Lymphoma (B-DLCL): A Multicenter Pilot Study.

Incidence of Invasive Aspergillosis in Allogeneic Stem Cell Transplantation Patients: An Italian Prospectic Multicenter Study.

Front-Line Treatment of Acute Promyelocytic Leukemia with AIDA Induction Followed by Risk-Adapted Consolidation: Results of the AIDA-2000 Trial of the Italian GIMEMA Group.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only